Skip to main content
Erschienen in: Current Cardiology Reports 3/2013

01.03.2013 | Ischemic Heart Disease (D Mukherjee, Section Editor)

Chronic Kidney Disease as a Coronary Artery Disease Risk Equivalent

verfasst von: Alexandrios Briasoulis, George L. Bakris

Erschienen in: Current Cardiology Reports | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

Chronic kidney disease (CKD) is associated with accelerated cardiovascular disease (CVD) risk and a higher CVD event rate. Substantial data from prospective cohort studies support the concept that dialysis patients as well as those with advanced stage (stages 3–5) CKD are associated with an increased risk for all-cause and cardiovascular mortality. The risk for coronary artery disease (CAD) increases exponentially with declining kidney function, i.e., stage 3 or higher CKD. Indeed, CVD accounts for more than 50 % of deaths in patients with CKD. CKD patients are more likely to die of CVD than to progress to end stage kidney disease. This increase in CV risk is commonly attributed to co-existence of numerous traditional and nontraditional risk factors for the development of CVD that frequently accompany reduced kidney function. Therefore, CKD itself is now considered an independent CVD risk factor and a coronary artery disease (CAD) equivalent for all-cause mortality. All patients at risk for CAD should be evaluated for kidney disease. Treatments used for management of established CAD might have similar benefits for patients with concomitant CKD.
Literatur
2.
Zurück zum Zitat Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–305.PubMedCrossRef Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–305.PubMedCrossRef
3.
Zurück zum Zitat •• Shroff GR, Frederick PD, Herzog CA. Renal failure and acute myocardial infarction: clinical characteristics in patients with advanced chronic kidney disease, on dialysis, and without chronic kidney disease. A collaborative project of the United States Renal Data System/National Institutes of Health and the National Registry of Myocardial Infarction. Am Heart J. 2012;163:399–406. This observational study used record-linked data from the US Renal Data System and Third National Registry of Myocardial Infarction to identify 2390 dialysis patients with myocardial infarction hospitalizations. It concludes that non-dialysis-dependent, advanced CKD patients who have had an acute myocardial infarction are similar to dialysis patients.PubMedCrossRef •• Shroff GR, Frederick PD, Herzog CA. Renal failure and acute myocardial infarction: clinical characteristics in patients with advanced chronic kidney disease, on dialysis, and without chronic kidney disease. A collaborative project of the United States Renal Data System/National Institutes of Health and the National Registry of Myocardial Infarction. Am Heart J. 2012;163:399–406. This observational study used record-linked data from the US Renal Data System and Third National Registry of Myocardial Infarction to identify 2390 dialysis patients with myocardial infarction hospitalizations. It concludes that non-dialysis-dependent, advanced CKD patients who have had an acute myocardial infarction are similar to dialysis patients.PubMedCrossRef
4.
Zurück zum Zitat Lindner A, Charra B, Sherrard DJ, Scribner BH. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med. 1974;290:697–701.PubMedCrossRef Lindner A, Charra B, Sherrard DJ, Scribner BH. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med. 1974;290:697–701.PubMedCrossRef
5.
Zurück zum Zitat Miyamoto T, Carrero JJ, Stenvinkel P. Inflammation as a risk factor and target for therapy in chronic kidney disease. Curr Opin Nephrol Hypertens. 2011;20:662–8.PubMedCrossRef Miyamoto T, Carrero JJ, Stenvinkel P. Inflammation as a risk factor and target for therapy in chronic kidney disease. Curr Opin Nephrol Hypertens. 2011;20:662–8.PubMedCrossRef
6.
Zurück zum Zitat Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375:2073–81.PubMedCrossRef Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375:2073–81.PubMedCrossRef
7.
Zurück zum Zitat • van der Velde M, Matsushita K, Coresh J, Astor BC, Woodward M, Levey AS, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int. 2011;79:1341–52. This is a collaborative meta-analysis of 10 cohorts with 266,975 patientsselected because of increased risk for chronic kidney disease, defined as a history of hypertension, diabetes, or cardiovascular disease. It found that an eGFR <45 ml/min/1.73 m 2 or albuminuria >300 mg/day were associated with an increase in all-cause and CV mortality.PubMedCrossRef • van der Velde M, Matsushita K, Coresh J, Astor BC, Woodward M, Levey AS, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int. 2011;79:1341–52. This is a collaborative meta-analysis of 10 cohorts with 266,975 patientsselected because of increased risk for chronic kidney disease, defined as a history of hypertension, diabetes, or cardiovascular disease. It found that an eGFR <45 ml/min/1.73 m 2 or albuminuria >300 mg/day were associated with an increase in all-cause and CV mortality.PubMedCrossRef
8.
Zurück zum Zitat Kalaitzidis RG, Bakris GL. Serum creatinine vs. albuminuria as biomarkers for the estimation of cardiovascular risk. Curr Vasc Pharmacol. 2010;8:604–11.PubMedCrossRef Kalaitzidis RG, Bakris GL. Serum creatinine vs. albuminuria as biomarkers for the estimation of cardiovascular risk. Curr Vasc Pharmacol. 2010;8:604–11.PubMedCrossRef
9.
Zurück zum Zitat Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108:2154–69.PubMedCrossRef Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108:2154–69.PubMedCrossRef
10.
Zurück zum Zitat Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003;139:137–47.PubMed Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003;139:137–47.PubMed
11.
Zurück zum Zitat •• Tonelli M, Muntner P, Lloyd A, Manns BJ, Klarenbach S, Pannu N, et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet. 2012;380:807–14. This is a population-based cohort with measures of estimated glomerular filtration rate (eGFR) and proteinuria from Alberta, Canada. Over a million people were studied and the results indicate that presence of Stage 3 CKD had a higher all-cause mortality than previous myocardial infarction.PubMedCrossRef •• Tonelli M, Muntner P, Lloyd A, Manns BJ, Klarenbach S, Pannu N, et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet. 2012;380:807–14. This is a population-based cohort with measures of estimated glomerular filtration rate (eGFR) and proteinuria from Alberta, Canada. Over a million people were studied and the results indicate that presence of Stage 3 CKD had a higher all-cause mortality than previous myocardial infarction.PubMedCrossRef
12.
Zurück zum Zitat Polonsky TS, Bakris GL. Chronic kidney disease: a coronary heart disease equivalent? Lancet. 2012;380:783–5.PubMedCrossRef Polonsky TS, Bakris GL. Chronic kidney disease: a coronary heart disease equivalent? Lancet. 2012;380:783–5.PubMedCrossRef
13.
Zurück zum Zitat Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension. 2001;38:938–42.PubMedCrossRef Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension. 2001;38:938–42.PubMedCrossRef
14.
Zurück zum Zitat Schwarz U, Buzello M, Ritz E, Stein G, Raabe G, Wiest G, et al. Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant. 2000;15:218–23.PubMedCrossRef Schwarz U, Buzello M, Ritz E, Stein G, Raabe G, Wiest G, et al. Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant. 2000;15:218–23.PubMedCrossRef
15.
Zurück zum Zitat Zuo Y, Yancey P, Castro I, Khan WN, Motojima M, Ichikawa I, et al. Renal dysfunction potentiates foam cell formation by repressing ABCA1. Arterioscler Thromb Vasc Biol. 2009;29:1277–82.PubMedCrossRef Zuo Y, Yancey P, Castro I, Khan WN, Motojima M, Ichikawa I, et al. Renal dysfunction potentiates foam cell formation by repressing ABCA1. Arterioscler Thromb Vasc Biol. 2009;29:1277–82.PubMedCrossRef
16.
Zurück zum Zitat Ewence AE, Bootman M, Roderick HL, Skepper JN, McCarthy G, Epple M, et al. Calcium phosphate crystals induce cell death in human vascular smooth muscle cells: a potential mechanism in atherosclerotic plaque destabilization. Circ Res. 2008;103:e28–34.PubMedCrossRef Ewence AE, Bootman M, Roderick HL, Skepper JN, McCarthy G, Epple M, et al. Calcium phosphate crystals induce cell death in human vascular smooth muscle cells: a potential mechanism in atherosclerotic plaque destabilization. Circ Res. 2008;103:e28–34.PubMedCrossRef
17.
Zurück zum Zitat Nadra I, Boccaccini AR, Philippidis P, Whelan LC, McCarthy GM, Haskard DO, et al. Effect of particle size on hydroxyapatite crystal-induced tumor necrosis factor alpha secretion by macrophages. Atherosclerosis. 2008;196:98–105.PubMedCrossRef Nadra I, Boccaccini AR, Philippidis P, Whelan LC, McCarthy GM, Haskard DO, et al. Effect of particle size on hydroxyapatite crystal-induced tumor necrosis factor alpha secretion by macrophages. Atherosclerosis. 2008;196:98–105.PubMedCrossRef
18.
Zurück zum Zitat Ehara S, Kobayashi Y, Yoshiyama M, Shimada K, Shimada Y, Fukuda D, et al. Spotty calcification typifies the culprit plaque in patients with acute myocardial infarction: an intravascular ultrasound study. Circulation. 2004;110:3424–9.PubMedCrossRef Ehara S, Kobayashi Y, Yoshiyama M, Shimada K, Shimada Y, Fukuda D, et al. Spotty calcification typifies the culprit plaque in patients with acute myocardial infarction: an intravascular ultrasound study. Circulation. 2004;110:3424–9.PubMedCrossRef
19.
Zurück zum Zitat Buzello M, Tornig J, Faulhaber J, Ehmke H, Ritz E, Amann K. The apolipoprotein e knockout mouse: a model documenting accelerated atherogenesis in uremia. J Am Soc Nephrol. 2003;14:311–6.PubMedCrossRef Buzello M, Tornig J, Faulhaber J, Ehmke H, Ritz E, Amann K. The apolipoprotein e knockout mouse: a model documenting accelerated atherogenesis in uremia. J Am Soc Nephrol. 2003;14:311–6.PubMedCrossRef
20.
Zurück zum Zitat Ishimura E, Shoji T, Emoto M, Motoyama K, Shinohara K, Matsumoto N, et al. Renal insufficiency accelerates atherosclerosis in patients with type 2 diabetes mellitus. Am J Kidney Dis. 2001;38:S186–90.PubMedCrossRef Ishimura E, Shoji T, Emoto M, Motoyama K, Shinohara K, Matsumoto N, et al. Renal insufficiency accelerates atherosclerosis in patients with type 2 diabetes mellitus. Am J Kidney Dis. 2001;38:S186–90.PubMedCrossRef
21.
Zurück zum Zitat Stinghen AE, Goncalves SM, Martines EG, Nakao LS, Riella MC, Aita CA, et al. Increased plasma and endothelial cell expression of chemokines and adhesion molecules in chronic kidney disease. Nephron Clin Pract. 2009;111:c117–26.PubMedCrossRef Stinghen AE, Goncalves SM, Martines EG, Nakao LS, Riella MC, Aita CA, et al. Increased plasma and endothelial cell expression of chemokines and adhesion molecules in chronic kidney disease. Nephron Clin Pract. 2009;111:c117–26.PubMedCrossRef
22.
Zurück zum Zitat Sela S, Shurtz-Swirski R, Cohen-Mazor M, Mazor R, Chezar J, Shapiro G, et al. Primed peripheral polymorphonuclear leukocyte: a culprit underlying chronic low-grade inflammation and systemic oxidative stress in chronic kidney disease. J Am Soc Nephrol. 2005;16:2431–8.PubMedCrossRef Sela S, Shurtz-Swirski R, Cohen-Mazor M, Mazor R, Chezar J, Shapiro G, et al. Primed peripheral polymorphonuclear leukocyte: a culprit underlying chronic low-grade inflammation and systemic oxidative stress in chronic kidney disease. J Am Soc Nephrol. 2005;16:2431–8.PubMedCrossRef
23.
Zurück zum Zitat Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database Syst Rev. 2008;CD007176. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database Syst Rev. 2008;CD007176.
24.
Zurück zum Zitat Takaya T, Kawashima S, Shinohara M, Yamashita T, Toh R, Sasaki N, et al. Angiotensin II type 1 receptor blocker telmisartan suppresses superoxide production and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. Atherosclerosis. 2006;186:402–10.PubMedCrossRef Takaya T, Kawashima S, Shinohara M, Yamashita T, Toh R, Sasaki N, et al. Angiotensin II type 1 receptor blocker telmisartan suppresses superoxide production and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. Atherosclerosis. 2006;186:402–10.PubMedCrossRef
25.
Zurück zum Zitat • Bakris GL. Lipid disorders in uremia and dialysis. Contrib Nephrol. 2012;178:100–5. Reviews the difference in lipid profiles and mechanisms that contribute to the differences. It compares lipid profiles of people with advanced CKD as well as dilaysis patients to those with normal kidney function.PubMedCrossRef • Bakris GL. Lipid disorders in uremia and dialysis. Contrib Nephrol. 2012;178:100–5. Reviews the difference in lipid profiles and mechanisms that contribute to the differences. It compares lipid profiles of people with advanced CKD as well as dilaysis patients to those with normal kidney function.PubMedCrossRef
26.
Zurück zum Zitat Bouvet C, Moreau S, Blanchette J, de Blois D, Moreau P. Sequential activation of matrix metalloproteinase 9 and transforming growth factor beta in arterial elastocalcinosis. Arterioscler Thromb Vasc Biol. 2008;28:856–62.PubMedCrossRef Bouvet C, Moreau S, Blanchette J, de Blois D, Moreau P. Sequential activation of matrix metalloproteinase 9 and transforming growth factor beta in arterial elastocalcinosis. Arterioscler Thromb Vasc Biol. 2008;28:856–62.PubMedCrossRef
27.
Zurück zum Zitat Villa-Bellosta R, Millan A, Sorribas V. Role of calcium-phosphate deposition in vascular smooth muscle cell calcification. Am J Physiol Cell Physiol. 2011;300:C210–20.PubMedCrossRef Villa-Bellosta R, Millan A, Sorribas V. Role of calcium-phosphate deposition in vascular smooth muscle cell calcification. Am J Physiol Cell Physiol. 2011;300:C210–20.PubMedCrossRef
28.
Zurück zum Zitat McCullough PA, Jurkovitz CT, Pergola PE, McGill JB, Brown WW, Collins AJ, et al. Independent components of chronic kidney disease as a cardiovascular risk state: results from the Kidney Early Evaluation Program (KEEP). Arch Intern Med. 2007;167:1122–9.PubMedCrossRef McCullough PA, Jurkovitz CT, Pergola PE, McGill JB, Brown WW, Collins AJ, et al. Independent components of chronic kidney disease as a cardiovascular risk state: results from the Kidney Early Evaluation Program (KEEP). Arch Intern Med. 2007;167:1122–9.PubMedCrossRef
29.
Zurück zum Zitat Tonelli M, Muntner P, Lloyd A, Manns BJ, James MT, Klarenbach S, et al. Using proteinuria and estimated glomerular filtration rate to classify risk in patients with chronic kidney disease: a cohort study. Ann Intern Med. 2011;154:12–21.PubMed Tonelli M, Muntner P, Lloyd A, Manns BJ, James MT, Klarenbach S, et al. Using proteinuria and estimated glomerular filtration rate to classify risk in patients with chronic kidney disease: a cohort study. Ann Intern Med. 2011;154:12–21.PubMed
30.
Zurück zum Zitat Jurkovitz CT, Abramson JL, Vaccarino LV, Weintraub WS, McClellan WM. Association of high serum creatinine and anemia increases the risk of coronary events: results from the prospective community-based atherosclerosis risk in communities (ARIC) study. J Am Soc Nephrol. 2003;14:2919–25.PubMedCrossRef Jurkovitz CT, Abramson JL, Vaccarino LV, Weintraub WS, McClellan WM. Association of high serum creatinine and anemia increases the risk of coronary events: results from the prospective community-based atherosclerosis risk in communities (ARIC) study. J Am Soc Nephrol. 2003;14:2919–25.PubMedCrossRef
31.
Zurück zum Zitat Fried LP, Kronmal RA, Newman AB, Bild DE, Mittelmark MB, Polak JF, et al. Risk factors for 5-year mortality in older adults: the Cardiovascular Health Study. JAMA. 1998;279:585–92.PubMedCrossRef Fried LP, Kronmal RA, Newman AB, Bild DE, Mittelmark MB, Polak JF, et al. Risk factors for 5-year mortality in older adults: the Cardiovascular Health Study. JAMA. 1998;279:585–92.PubMedCrossRef
32.
Zurück zum Zitat Foley RN, Wang C, Collins AJ. Cardiovascular risk factor profiles and kidney function stage in the US general population: the NHANES III study. Mayo Clin Proc. 2005;80:1270–7.PubMedCrossRef Foley RN, Wang C, Collins AJ. Cardiovascular risk factor profiles and kidney function stage in the US general population: the NHANES III study. Mayo Clin Proc. 2005;80:1270–7.PubMedCrossRef
33.
Zurück zum Zitat Weiner DE, Tighiouart H, Elsayed EF, Griffith JL, Salem DN, Levey AS, et al. The Framingham predictive instrument in chronic kidney disease. J Am Coll Cardiol. 2007;50:217–24.PubMedCrossRef Weiner DE, Tighiouart H, Elsayed EF, Griffith JL, Salem DN, Levey AS, et al. The Framingham predictive instrument in chronic kidney disease. J Am Coll Cardiol. 2007;50:217–24.PubMedCrossRef
34.
Zurück zum Zitat • Clase CM, Gao P, Tobe SW, McQueen MJ, Grosshennig A, Teo KK, et al. Estimated glomerular filtration rate and albuminuria as predictors of outcomes in patients with high cardiovascular risk: a cohort study. Ann Intern Med. 2011;154:310–8. Reviews role eGFR and albuminuria in people with CKD from the ONTARGET study in the context of CV risk.PubMed • Clase CM, Gao P, Tobe SW, McQueen MJ, Grosshennig A, Teo KK, et al. Estimated glomerular filtration rate and albuminuria as predictors of outcomes in patients with high cardiovascular risk: a cohort study. Ann Intern Med. 2011;154:310–8. Reviews role eGFR and albuminuria in people with CKD from the ONTARGET study in the context of CV risk.PubMed
35.
Zurück zum Zitat Wattanakit K, Coresh J, Muntner P, Marsh J, Folsom AR. Cardiovascular risk among adults with chronic kidney disease, with or without prior myocardial infarction. J Am Coll Cardiol. 2006;48:1183–9.PubMedCrossRef Wattanakit K, Coresh J, Muntner P, Marsh J, Folsom AR. Cardiovascular risk among adults with chronic kidney disease, with or without prior myocardial infarction. J Am Coll Cardiol. 2006;48:1183–9.PubMedCrossRef
36.
Zurück zum Zitat Deo R, Fyr CL, Fried LF, Newman AB, Harris TB, Angleman S, et al. Kidney dysfunction and fatal cardiovascular disease—an association independent of atherosclerotic events: results from the Health, Aging, and Body Composition (Health ABC) study. Am Heart J. 2008;155:62–8.PubMedCrossRef Deo R, Fyr CL, Fried LF, Newman AB, Harris TB, Angleman S, et al. Kidney dysfunction and fatal cardiovascular disease—an association independent of atherosclerotic events: results from the Health, Aging, and Body Composition (Health ABC) study. Am Heart J. 2008;155:62–8.PubMedCrossRef
37.
Zurück zum Zitat •• Mahmoodi BK, Matsushita K, Woodward M, Blankestijn PJ, Cirillo M, Ohkubo T, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis. Lancet. 2012;380(9854):1649–61. Data from 45 cohorts with 1, 127, 656 participants was analyzed, 364 344 of whom had hypertension. Low eGFR and high albuminuria were associated with mortality irrespective of hypertensive status in the general population and high-risk cohorts.PubMedCrossRef •• Mahmoodi BK, Matsushita K, Woodward M, Blankestijn PJ, Cirillo M, Ohkubo T, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis. Lancet. 2012;380(9854):1649–61. Data from 45 cohorts with 1, 127, 656 participants was analyzed, 364 344 of whom had hypertension. Low eGFR and high albuminuria were associated with mortality irrespective of hypertensive status in the general population and high-risk cohorts.PubMedCrossRef
38.
Zurück zum Zitat •• Fox CS, Matsushita K, Woodward M, Bilo HJ, Chalmers J, Heerspink HJ, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet. 2012;380(9854):1662–73. Data from 1, 024, 977 participants (128 505 with diabetes) from 30 general population and high-risk cardiovascular cohorts and 13 chronic kidney disease cohorts was analyzed. Those with diabetes and CKD had the highest mortality risk, however, those with CKD had a higher mortality risk than those with diabetes and no CKD.PubMedCrossRef •• Fox CS, Matsushita K, Woodward M, Bilo HJ, Chalmers J, Heerspink HJ, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet. 2012;380(9854):1662–73. Data from 1, 024, 977 participants (128 505 with diabetes) from 30 general population and high-risk cardiovascular cohorts and 13 chronic kidney disease cohorts was analyzed. Those with diabetes and CKD had the highest mortality risk, however, those with CKD had a higher mortality risk than those with diabetes and no CKD.PubMedCrossRef
39.
Zurück zum Zitat • Siasos G, Tousoulis D, Michalea S, Oikonomou E, Kolia C, Kioufis S, et al. Biomarkers determining cardiovascular risk in patients with kidney disease. Curr Med Chem. 2012;19:2555–71. This is a nice review of the state of biomarkers in determining CV risk in people with CKD.PubMedCrossRef • Siasos G, Tousoulis D, Michalea S, Oikonomou E, Kolia C, Kioufis S, et al. Biomarkers determining cardiovascular risk in patients with kidney disease. Curr Med Chem. 2012;19:2555–71. This is a nice review of the state of biomarkers in determining CV risk in people with CKD.PubMedCrossRef
40.
Zurück zum Zitat • Slinin Y, Ishani A, Rector T, Fitzgerald P, Macdonald R, Tacklind J, et al. Management of hyperglycemia, dyslipidemia, and albuminuria in patients with diabetes and CKD: a systematic review for a KDOQI Clinical Practice Guideline. Am J Kidney Dis. 2012;60:747–69. This is a systematic review of studies evalauting glycemic control and lipid lowering in CKD. It demonstrates that glycemic control does not slow nephropathy progression or significantly reduce mortality in CKD while lipid lowering trends toward reducing mortality in CKD.PubMedCrossRef • Slinin Y, Ishani A, Rector T, Fitzgerald P, Macdonald R, Tacklind J, et al. Management of hyperglycemia, dyslipidemia, and albuminuria in patients with diabetes and CKD: a systematic review for a KDOQI Clinical Practice Guideline. Am J Kidney Dis. 2012;60:747–69. This is a systematic review of studies evalauting glycemic control and lipid lowering in CKD. It demonstrates that glycemic control does not slow nephropathy progression or significantly reduce mortality in CKD while lipid lowering trends toward reducing mortality in CKD.PubMedCrossRef
41.
Zurück zum Zitat Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377:2181–92.PubMedCrossRef Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377:2181–92.PubMedCrossRef
42.
Zurück zum Zitat Kalaitzidis RG, Bakris GL. Pros and cons of aggressive blood pressure lowering in patients with type 2 diabetes. Curr Vasc Pharmacol. 2012;10:156–61.PubMedCrossRef Kalaitzidis RG, Bakris GL. Pros and cons of aggressive blood pressure lowering in patients with type 2 diabetes. Curr Vasc Pharmacol. 2012;10:156–61.PubMedCrossRef
Metadaten
Titel
Chronic Kidney Disease as a Coronary Artery Disease Risk Equivalent
verfasst von
Alexandrios Briasoulis
George L. Bakris
Publikationsdatum
01.03.2013
Verlag
Current Science Inc.
Erschienen in
Current Cardiology Reports / Ausgabe 3/2013
Print ISSN: 1523-3782
Elektronische ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-012-0340-4

Weitere Artikel der Ausgabe 3/2013

Current Cardiology Reports 3/2013 Zur Ausgabe

New Therapies for Cardiovascular Disease (K Mahaffey, Section Editor)

PCSK9 Inhibitors: Potential in Cardiovascular Therapeutics

Cardiac PET, CT, and MRI (S Achenbach, Section Editor)

PET and SPECT in Heart Failure

Echocardiography (RM Lang, Section Editor)

Interventional Echocardiography in Structural Heart Disease

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Vorhofflimmern bei Jüngeren gefährlicher als gedacht

06.05.2024 Vorhofflimmern Nachrichten

Immer mehr jüngere Menschen leiden unter Vorhofflimmern. Betroffene unter 65 Jahren haben viele Risikofaktoren und ein signifikant erhöhtes Sterberisiko verglichen mit Gleichaltrigen ohne die Erkrankung.

Chronisches Koronarsyndrom: Gefahr von Hospitalisierung wegen Herzinsuffizienz

06.05.2024 Herzinsuffizienz Nachrichten

Obwohl ein rezidivierender Herzinfarkt bei chronischem Koronarsyndrom wahrscheinlich die Hauptsorge sowohl der Patienten als auch der Ärzte ist, sind andere Ereignisse womöglich gefährlicher. Laut einer französischen Studie stellt eine Hospitalisation wegen Herzinsuffizienz eine größere Gefahr dar.

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.